See more : Free Flow, Inc. (FFLO) Income Statement Analysis – Financial Results
Complete financial analysis of Better Therapeutics, Inc. (BTTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Better Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Indivior PLC (IZQVF) Income Statement Analysis – Financial Results
- Shenzhen JPT Opto-Electronics Co., Ltd. (688025.SS) Income Statement Analysis – Financial Results
- Legato Merger Corp. III (LEGT) Income Statement Analysis – Financial Results
- Hawaiian Electric Company, Inc. PFD C 4.25% (HAWEN) Income Statement Analysis – Financial Results
- Exagen Inc. (XGN) Income Statement Analysis – Financial Results
Better Therapeutics, Inc. (BTTX)
About Better Therapeutics, Inc.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.00K | 18.00K |
| Cost of Revenue | 2.73M | 1.62M | 682.00K | 898.00K |
| Gross Profit | -2.73M | -1.62M | -674.00K | -880.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -8,425.00% | -4,888.89% |
| Research & Development | 16.44M | 19.44M | 2.98M | 2.29M |
| General & Administrative | 14.84M | 8.79M | 2.46M | 2.20M |
| Selling & Marketing | 6.98M | 2.34M | 216.00K | 406.00K |
| SG&A | 21.82M | 11.12M | 2.67M | 2.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.26M | 30.56M | 5.65M | 4.89M |
| Cost & Expenses | 38.26M | 30.56M | 6.33M | 5.79M |
| Interest Income | 1.49K | 185.00 | 100.00 | 11.00 |
| Interest Expense | 1.49M | 185.00K | 100.00K | 11.00K |
| Depreciation & Amortization | 2.73M | 1.62M | 75.00K | 72.00K |
| EBITDA | -38.26M | -30.56M | -6.25M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | -78,100.00% | -31,672.22% |
| Operating Income | -38.26M | -30.56M | -6.32M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | -79,037.50% | -32,072.22% |
| Total Other Income/Expenses | -1.49M | -9.93M | 89.00K | -11.00K |
| Income Before Tax | -39.75M | -40.49M | -6.23M | -5.78M |
| Income Before Tax Ratio | 0.00% | 0.00% | -77,925.00% | -32,133.33% |
| Income Tax Expense | 7.00K | -153.00K | 153.00K | 11.00K |
| Net Income | -39.76M | -40.34M | -6.39M | -5.80M |
| Net Income Ratio | 0.00% | 0.00% | -79,837.50% | -32,194.44% |
| EPS | -1.69 | -1.71 | -0.85 | -0.25 |
| EPS Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Avg Shares Out | 23.56M | 23.60M | 7.56M | 23.60M |
| Weighted Avg Shares Out (Dil) | 23.56M | 23.60M | 7.56M | 23.60M |
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
NEW YORK--(BUSINESS WIRE)--Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX) (the “Company”) announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a wind-down of the Company. This decision...
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced a major partnership with the American College of Lifestyle Medicine's (ACLM) National Training Initiative (NTI), aimed at...
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the acceptance of a late-breaking abstract presenting 180-day outcomes data and its participation at the 17th International...
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, March...
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
Better Therapeutics' (BTTX) novel CBT platform attains the FDA's breakthrough device designation to improve patient care in the treatment of liver and metabolic diseases.
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive...
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that it has entered into a rebate agreement with one of the nation's leading Pharmacy Benefit Managers...
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D),...
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a partnership to integrate Better...
Source: https://incomestatements.info
Category: Stock Reports